Infant Bacterial Therapeutics Logo

Infant Bacterial Therapeutics

IBT | ST

Overview

Corporate Details

ISIN(s):
SE0008015242 (+3 more)
LEI:
2138008KVBXCRJGP6Z26
Country:
Sweden
Address:
Bryggargatan 10, 111 21 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Infant Bacterial Therapeutics (IBT) is a pharmaceutical company dedicated to the development and commercialization of novel drugs for rare diseases affecting premature infants. The company's pipeline is focused on addressing urgent unmet medical needs, particularly the prevention of necrotizing enterocolitis (NEC), a life-threatening intestinal disease. IBT's core strategy involves developing therapies that influence the human infant microbiome. Its lead candidate, IBP-9414, is a first-in-class New Biological Entity (NBE) currently undergoing a pivotal Phase 3 clinical evaluation known as 'The Connection Study.' IBT aims to secure regulatory approval from major agencies, including the FDA and EMA, for its therapeutic products.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Infant Bacterial Therapeutics. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-20 08:00
Interim Report
Swedish 586.0 KB
2025-08-20 08:00
Interim Report
English 565.3 KB
2025-05-08 17:45
Post-Annual General Meeting Information
Annual General Meeting of Infant Bacterial Therapeutics
English 41.0 KB
2025-05-08 17:45
Post-Annual General Meeting Information
Årsstämma i Infant Bacterial Therapeutics
Swedish 40.6 KB
2025-05-07 14:30
Quarterly Report
Swedish 550.1 KB
2025-05-07 14:30
Quarterly Report
English 549.5 KB
2025-02-13 08:30
Earnings Release
Swedish 577.8 KB
2025-02-13 08:30
Annual Report
English 571.2 KB
2024-08-28 08:30
Interim Report
Swedish 578.3 KB
2024-08-28 08:30
Interim Report
English 594.7 KB
2024-08-15 16:44
Regulatory News Service
Infant Bacterial Therapeutics patent godkänt i USA
Swedish 48.9 KB
2024-08-15 16:44
Regulatory News Service
Patent for Infant Bacterial Therapeutics has been approved in the USA
English 48.4 KB
2024-07-08 16:40
Regulatory News Service
“The Connection Study” is completed
English 52.7 KB
2024-07-08 16:40
Regulatory News Service
“The Connection Study” är avslutad
Swedish 53.8 KB
2024-05-08 18:11
Post-Annual General Meeting Information
Annual General Meeting of Infant Bacterial Therapeutics
English 44.2 KB

Automate Your Workflow. Get a real-time feed of all Infant Bacterial Therapeutics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Infant Bacterial Therapeutics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-11-14 Maria Ekdahl Other Buy 500 17,000.00 SEK
2024-02-08 Anthon Jahreskog Other Buy 839 79,033.80 SEK
2024-02-08 Anthon Jahreskog Other Buy 161 15,134.00 SEK
2023-06-09 Maria Ekdahl Other Buy 1,086 49,956.00 SEK
2023-05-23 Anders Kronström Other Buy 1,329 56,482.50 SEK
2023-05-23 Anthon Jahreskog Other Buy 851 36,593.00 SEK
2023-05-23 Maria Ekdahl Other Buy 465 19,995.00 SEK
2023-05-23 Anthon Jahreskog Other Buy 149 6,377.20 SEK
2023-05-23 Anthon Jahreskog Other Buy 149 6,269.92 SEK
2023-05-22 Maria Ekdahl Other Buy 709 30,487.00 SEK

Peer Companies

Company Country Ticker View
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Makes saliva-based diagnostics accessible for at-home & pro health & drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AGRONOMICS LIMITED Logo Isle of Man ANIC
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK